|
2.11 Etiologie - Alimentation
|
|
|
|
Red Meat Increases Risk of Dying From 9 Diseases [NY Times]
|
|
|
|
|
|
White
meat, on the other hand, may be good for you. The researchers found
that those who ate the highest proportion of white meat had a 25 percent
reduced risk of dying from various causes compared with those who ate
the least white meat.
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
5. Traitements
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
FDA Approves Three Immunotherapy Drugs for Patients with Bladder Cancer [NCI]
|
|
|
|
|
|
The
Food and Drug Administration (FDA) in recent weeks has approved three
immunotherapy drugs for bladder cancer, bringing the total number of
approved immunotherapies for this disease to four. Known as checkpoint
inhibitors, all four drugs work by “releasing the brakes” on the immune
system and allowing immune cells to attack tumors.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6. Lutte contre les cancers
|
|
|
Richard Lehman’s journal review—15 May 2017 [BMJ Blogs]
|
|
|
|
|
|
But
the elephant in this room is the histological diagnosis of thyroid
cancer. How is it that in 2017 we can follow the genomic patterns of so
many cancers with exquisite precision and yet utterly fail to
distinguish between harmless and progressive forms of thyroid “cancer”?
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.11 Patients
|
|
|
Helping patients after cancer treatment [Stanford Medicine]
|
|
|
|
|
|
A
multi-specialty team of oncologists, nurses, social workers and other
specialists work together to a post-treatment plan for each patient and
their family. Our staff helps patients emotionally process their
experience, cope with issues like financial anxiety, altered body image,
confidence and intimacy.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Citation Performance Indicators — A Very Short Introduction [The Scholarly Kitchen]
|
|
|
|
|
|
The
purpose of this post is to provide a brief summary of the main citation
indicators used today. It is not intended to be comprehensive, nor is
it intended to opine on which indicator is best. It is geared for casual
users of performance metrics and not bibliometricians. No indicator is
perfect; the goal of the table below is simply to highlight their
salient strengths and weaknesses.
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|